UBS Group’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $18.1M | Buy |
1,589,040
+915,893
| +136% | +$10.4M | ﹤0.01% | 1939 |
|
|
2025
Q1 | $8M | Buy |
673,147
+598,034
| +796% | +$7.1M | ﹤0.01% | 2575 |
|
|
2024
Q4 | $1.42M | Sell |
75,113
-27,753
| -27% | -$523K | ﹤0.01% | 3975 |
|
|
2024
Q3 | $2.31M | Sell |
102,866
-15,697
| -13% | -$353K | ﹤0.01% | 2918 |
|
|
2024
Q2 | $2.47M | Sell |
118,563
-50,379
| -30% | -$1.05M | ﹤0.01% | 2664 |
|
|
2024
Q1 | $2.48M | Buy |
168,942
+92,540
| +121% | +$1.36M | ﹤0.01% | 2790 |
|
|
2023
Q4 | $788K | Sell |
76,402
-95,600
| -56% | -$987K | ﹤0.01% | 3606 |
|
|
2023
Q3 | $1.35M | Buy |
172,002
+91,355
| +113% | +$718K | ﹤0.01% | 2868 |
|
|
2023
Q2 | $806K | Sell |
80,647
-4,461
| -5% | -$44.6K | ﹤0.01% | 3463 |
|
|
2023
Q1 | $756K | Sell |
85,108
-59,194
| -41% | -$526K | ﹤0.01% | 3396 |
|
|
2022
Q4 | $1.58M | Buy |
144,302
+102,511
| +245% | +$1.13M | ﹤0.01% | 2749 |
|
|
2022
Q3 | $545K | Sell |
41,791
-17,550
| -30% | -$229K | ﹤0.01% | 3297 |
|
|
2022
Q2 | $752K | Sell |
59,341
-89,363
| -60% | -$1.13M | ﹤0.01% | 3078 |
|
|
2022
Q1 | $2.08M | Buy |
148,704
+49,367
| +50% | +$692K | ﹤0.01% | 2625 |
|
|
2021
Q4 | $2.88M | Buy |
99,337
+98,762
| +17,176% | +$2.86M | ﹤0.01% | 2587 |
|
|
2021
Q3 | $17K | Sell |
575
-18,958
| -97% | -$560K | ﹤0.01% | 6203 |
|
|
2021
Q2 | $518K | Sell |
19,533
-12,909
| -40% | -$342K | ﹤0.01% | 3729 |
|
|
2021
Q1 | $1.01M | Buy |
+32,442
| New | +$1.01M | ﹤0.01% | 3343 |
|